Table 1.

Demographic characteristics.

Patients, n	2,518,034
Gender, n (%)
Female	1,302,709 (51.7)
Male	1,215,325 (48.3)
Age, n (%)
Children (<18 years old)	476,805 (18.9)
Adults (<=65 years old)	2,041,229 (81.1)
Length of follow-up (days)(mean ± SD)	2571 ± 490
Epilepsy prevalence, n (%)
All ages	10,041 (0.4)
Children (<18 years old)	1,796 (0.4)
Adults (<=65 years old)	8,245 (0.4)
Autoimmune disease prevalence, n (%)
Type 1 diabetes	43,704 (1.7)
Psoriasis	23,542 (0.9)
Rheumatoid arthritis	22,890 (0.9)
Ulcerative colitis	10,690 (0.4)
Hashimoto’s thyroiditis	9,830 (0.4)
Grave’s disease	9,758 (0.4)
Systemic lupus erythematosus	9,696 (0.4)
Crohn’s disease	8,774 (0.3)
Antiphospholipid syndrome	5,423 (0.2)
Sjögren’s Syndrome	3,614 (0.1)
Celiac disorder	1,885 (0.1)
Myasthenia gravis	1,070 (0.04)
Any of the above AD	137,398 (5.5)
Medications*, n (%)
Aminosalicylates	24,303 (1.0)
Disease-modifying antirheumatic drugs	33,557 (1.3)
Systemic glucocorticoids	790,045 (31.4)
Anti-TNF agents	7,114 (0.3)
Other biologics	2,915 (0.1)
Non-steroidal anti-inflammatory agents	945,892 (37.6)

(*excluding medications taken after the first epileptic seizure)